Next-generation antibody-based therapies in neurology

Ruck T, Nimmerjahn F, Wiendl H, Luenemann JD (2021)

Publication Type: Journal article, Review article

Publication year: 2021

Journal

Brain Oxford University Press

DOI: 10.1093/brain/awab465

Abstract

Ruck et al. describe recent developments in next-generation antibody-based therapies for brain diseases, including progress in Fc engineering, and efforts to improve the bioavailability of antibody-based platforms in CNS parenchyma. They highlight the potential benefits as well as limitations of such therapies in neurology.

Authors with CRIS profile

Falk Nimmerjahn Lehrstuhl für Genetik

Involved external institutions

Universitätsklinikum Münster DE Germany (DE)

How to cite

APA:

Ruck, T., Nimmerjahn, F., Wiendl, H., & Luenemann, J.D. (2021). Next-generation antibody-based therapies in neurology. Brain. https://dx.doi.org/10.1093/brain/awab465

MLA:

Ruck, Tobias, et al. "Next-generation antibody-based therapies in neurology." Brain (2021).

BibTeX: Download